Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating yesterday.
Mani Foroohar has given his Hold rating due to a combination of factors related to Alnylam Pharma’s current and future prospects. The company’s recent R&D Day highlighted its diverse pipeline and ambitious goals, including the development of nucresiran and its pivotal trial design. However, the aggressive timeline for approval by 2030, amidst a competitive landscape with several approved agents, raises concerns about the feasibility of these targets.
Additionally, while the updated data on vutrisiran and other assets like zilebesiran and mivelsiran show promise, there remains ongoing debate about the magnitude of their benefits, particularly in combination therapies. Alnylam’s strategic plans to expand into new tissues and improve RNAi manufacturing are noteworthy, but the stock’s performance is expected to be largely influenced by the upcoming vutrisiran launch in the ATTR-CM market over the next 12 to 18 months. These factors collectively contribute to the Hold rating, reflecting both the potential and the uncertainties in Alnylam’s future trajectory.
In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $284.00 price target.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.